We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQVIA Introduces SaaS Based eConsent Tool for Clinical Trials
Read MoreHide Full Article
IQVIA Holdings Inc. (IQV - Free Report) unveiled a Software as a Service (“SaaS”) eConsent tool for use in clinical trials yesterday.
Known as Informed Consent Form (ICF), the digital tool enables sites, sponsors and contract research organizations to develop their own ICFs and get them delivered through eConsent or traditional paper. It can be utilized with online as well as offline consent protocols.
ICF Author provides tools, training and best-practice resources for creation, management and automation of consent solutions. It reduces time as well as cost of development and implementation along with common audit issues concerning good clinical practices. It implements automatic scalability and provides complete control.
Tal Rosenberg, senior vice president, Global Technology Solutions at IQVIA, stated, “This product opens up the realm of eConsent to anyone and everyone.”
In a year’s time, shares of IQVIA have gained 14.1%, against the 11.6% decline of the industry it belongs to.
Our Take
We believe that the new offering will boost the Technology & Analytics Solutions segment that provides SaaS solutions that support a vast range of clinical and commercial processes.
The segment performed well in the last reported quarter, with revenues increasing 12.9% year over year on a reported basis and 15% on a constant-currency basis.
The long-term expected EPS (three to five years) growth rate for Paychex, Genpact and WEX is 8.5%, 10% and 15%, respectively.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
IQVIA Introduces SaaS Based eConsent Tool for Clinical Trials
IQVIA Holdings Inc. (IQV - Free Report) unveiled a Software as a Service (“SaaS”) eConsent tool for use in clinical trials yesterday.
Known as Informed Consent Form (ICF), the digital tool enables sites, sponsors and contract research organizations to develop their own ICFs and get them delivered through eConsent or traditional paper. It can be utilized with online as well as offline consent protocols.
ICF Author provides tools, training and best-practice resources for creation, management and automation of consent solutions. It reduces time as well as cost of development and implementation along with common audit issues concerning good clinical practices. It implements automatic scalability and provides complete control.
Tal Rosenberg, senior vice president, Global Technology Solutions at IQVIA, stated, “This product opens up the realm of eConsent to anyone and everyone.”
In a year’s time, shares of IQVIA have gained 14.1%, against the 11.6% decline of the industry it belongs to.
Our Take
We believe that the new offering will boost the Technology & Analytics Solutions segment that provides SaaS solutions that support a vast range of clinical and commercial processes.
The segment performed well in the last reported quarter, with revenues increasing 12.9% year over year on a reported basis and 15% on a constant-currency basis.
Zacks Rank and Stocks to Consider
Currently, IQVIA is a Zacks Rank #3 (Hold) stock.
A few better-ranked stocks in the broader Business Services sector include Paychex, Inc. (PAYX - Free Report) , Genpact Ltd. (G - Free Report) and WEX Inc. (WEX - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The long-term expected EPS (three to five years) growth rate for Paychex, Genpact and WEX is 8.5%, 10% and 15%, respectively.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>